Piperazine Compounds Targeting 5-HT1A Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression and anxiety, such as selective serotonin reuptake inhibitors (SSRIs), often lead to undesirable side effects and lack specificity in activating serotonin receptors, necessitating the development of more tolerable and effective drugs that target the 5-HT1A receptor.
Innovation Solution
Development of piperazine compounds represented by Formula (I) and their pharmaceutically acceptable salts, which act as 5-HT1A receptor agonists or partial agonists, providing a unique pharmacological profile for treating depression and anxiety without causing weight gain, sedation, or sexual dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If selective serotonin reuptake inhibitors (SSRIs) are used to treat depression and anxiety, then serotonin receptor activation is enhanced, but undesirable side effects occur due to indiscriminate activation of all serotonin receptors
Solution Approach 1:
The invention segments the non-specific action of SSRIs on multiple serotonin receptors into a targeted action on the specific 5-HT1A receptor subtype. The piperazine compounds are designed to selectively bind to 5-HT1A receptors, dividing the therapeutic effect from the harmful non-specific activation of other serotonin receptor subtypes.
Solution Approach 2:
The invention applies local quality by creating compounds with specific molecular structures (piperazine derivatives with particular substituent patterns) that are tailored to interact specifically with the 5-HT1A receptor binding site. This localized molecular design ensures selective activation of only the desired receptor subtype, avoiding activation of other serotonin receptors that cause side effects.
2Reliability
If traditional antidepressants are used to treat depression and anxiety, then therapeutic effects are achieved, but weight gain, sedation, and sexual dysfunction occur
Solution Approach 1:
The invention segments the broad pharmacological action of traditional antidepressants into a focused action on 5-HT1A receptors. By designing piperazine compounds that selectively target this specific receptor subtype, the therapeutic benefits are maintained while the harmful effects associated with activation of other receptor pathways are eliminated.
Solution Approach 2:
The piperazine compounds act as selective intermediaries that mediate the therapeutic effect through 5-HT1A receptor activation only. These compounds serve as a bridge between the need for antidepressant efficacy and the desire to avoid side effects, providing a selective pathway for therapeutic action without triggering the harmful responses associated with non-specific serotonin receptor activation.
3Object-generated harmful factors
If 5-HT1A agonists are used to treat depression, then weight gain, sedation, and sexual dysfunction are avoided, but the need for highly selective compounds with improved tolerability remains
Solution Approach 1:
The invention applies parameter changes by systematically modifying the piperazine molecular structure (varying substituents at different positions, changing chain lengths, adjusting aromatic groups) to optimize the balance between 5-HT1A receptor selectivity and therapeutic efficacy. These structural parameter adjustments fine-tune the compound's pharmacological profile to achieve both high selectivity and adequate efficacy.
Data Source
AI summary
The present invention relates to novel piperazine derivatives or pharmaceutically acceptable salts thereof, a process for preparing the same, and in particular, a high binding for Serotonin 1A(5-hydroxytryptamine; 5-HT1A) receptor, a pharmaceutical composition for treatment and/or prevention of depression and anxiety including an effective amount of the piperazine compound, and a method of treating depression, anxiety and other conditions related to 5-HT1A receptor in a mammal.